亿德体育
About Henlius
Company Profile
亿德体育:Corporate Culture
Honor
亿德体育:Board of Directors
Management Team
亿德体育:Advisory Committee
Product
亿德体育:Marketed Products
Products in R&D
Clinical Trial
Science & Technology
亿德体育:R&D Result
Innovation Centre
Technology Platform
亿德体育:Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
亿德体育:Financial Reports
Stock Info
IR Calendar
Investor Presentation
亿德体育:Analyst Coverage
亿德体育:Contact Information
Media
Press Release
Multi-media
亿德体育:Media Reports
亿德体育:Media Enquiry
Careers
亿德体育:Talent Philosophy
Staff Life
Training and Development
亿德体育:Contact Us
Contact Information
Customer Message
Privacy
亿德体育:Legal Statement
亿德体育:Compliance
EN
简体
EN
繁體
Home
About Henlius
亿德体育:Company Profile
亿德体育:Corporate Culture
Honor
Board of Directors
Management Team
亿德体育:Advisory Committee
Product
Marketed Products
亿德体育:Products in R&D
亿德体育:Clinical Trial
亿德体育:Science & Technology
亿德体育:R&D Result
Innovation Centre
亿德体育:Technology Platform
亿德体育:Quality Management
亿德体育:Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
亿德体育:Corporate Governance
亿德体育:Financial Reports
Stock Info
IR Calendar
亿德体育:Investor Presentation
Analyst Coverage
Contact Information
Media
亿德体育:Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
亿德体育:Popular Science
Media Reports
亿德体育:Media Enquiry
Careers
亿德体育:Talent Philosophy
Staff Life
Training and Development
亿德体育:Job Opportunities
亿德体育:Contact Us
Contact Information
Customer Message
Privacy
亿德体育:Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2024-09-21
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024-09-18
Latest Results of HANSIZHUANG and HANQUYOU Released at 2024 ESMO
2024-09-13
Meet Henlius at CPHI Worldwide 2024
2024-09-09
Latest Results of Serplulimab in the Field of SCLC Released at 2024 WCLC
2024-09-02
IND Application of Henlius’ Pembrolizumab Biosimilar Approved by NMPA
2024-08-26
Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1
2024-08-22
Henlius Trastuzumab Receives Approval in Canada
2024-08-20
Henlius and Convalife Reach Global Strategic Cooperation on Neratinib
2024-08-08
First Patient Dosed of Phase 2 Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein in Combination with Serplulimab Plus HANBEITAI for the First-line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients
1
2
3
...
7
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
亿德体育|亿德体育官网 - 登录入口
米乐m6 | m6米乐
米乐m6 - 官网登录
米乐m6 - 米乐m6官网
米乐m6 - 米乐m6官网 - APP下载